Coram, Inc.

Client Profile
Coram Healthcare Corporation, (“Corma” or the “Company”), a publicly-traded company, is the country’s largest provider of home infusion therapy products and services with revenue in excess of $400 million.
Situation
After two plans of reorganization were rejected by the Bankruptcy Court, SSG was retained to provide various valuation services and to facilitate the Company’s emergence from bankruptcy through a sale or restructuring.
Solution
To date, valuation services have included: enterprise valuation for the purposes of calculating the impairment of goodwill in order to comply with FAS 142; valuation to calculate the exchange of Senior Notes to Series B; preferred stock in order for the Debtor to comply with the regulatory requirements of Stark II; preferred stock valuation. SSG also provided expert testimony in Bankruptcy Court related to the aforementioned valuations.